6,401 results match your criteria Acta haematologica[Journal]


"Mixed" Myeloproliferative Neoplasm Due to Co-Occurrence of Different Driver Mutations.

Authors:
Isabelle Plo

Acta Haematol 2019 Apr 18;141(4):268-270. Epub 2019 Apr 18.

INSERM, UMR1170, Laboratory of Excellence GR-Ex, Villejuif, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000498979DOI Listing

Determination of Circulating Endothelial Cells and Endothelial Progenitor Cells Using Multicolor Flow Cytometry in Patients with Thrombophilia.

Acta Haematol 2019 Apr 17:1-7. Epub 2019 Apr 17.

Institute of Medical Biochemistry and Laboratory Diagnostics, Thrombotic Center, General University Hospital, and First Faculty of Medicine, Charles University, Prague, Czech Republic.

Background/aims: Endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) have been described as markers of endothelial damage and dysfunction in several diseases, including deep venous thrombosis. Their role in patients with known thrombophilia has not yet been evaluated. Both EPCs and CECs represent extremely rare cell populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499524DOI Listing
April 2019
1 Read

The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy.

Acta Haematol 2019 Apr 10;142(1):13-20. Epub 2019 Apr 10.

Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.

Cancer-related anemia (CRA) is a commonly occurring problem for patients with cancer regardless of whether they are receiving treatment with chemotherapy or immunotherapy. It may result from one or more processes (decreased production, increased destruction, or increased loss of red blood cells, RBC). Perturbations in iron availability form the primary basis for anemia in many patients with cancer-related anemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496967DOI Listing
April 2019
1 Read

Management of Perioperative Iron Deficiency Anemia.

Acta Haematol 2019 Apr 10;142(1):21-29. Epub 2019 Apr 10.

Department of Surgical Specialties, Biochemistry, and Immunology, School of Medicine, University of Málaga, Málaga, Spain,

Preoperative anemia affects 30-40% of patients undergoing major surgery and is an independent risk factor for perioperative blood transfusion, morbidity, and mortality. Absolute or functional iron deficiency is its leading cause. Nonanemic hematinic deficiencies are also prevalent and may hamper preoperative hemoglobin optimization and/or recovery from postoperative anemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496965DOI Listing

Posttransplantation Anemia in Kidney Transplant Recipients.

Acta Haematol 2019 Apr 10;142(1):37-43. Epub 2019 Apr 10.

Nephrology and Transplantation Immunology Laboratory, Rabin Medical Center, Petah Tikva, Israel.

Posttransplantation anemia (PTA) is common among kidney transplant patients. Early PTA is usually defined as anemia which develops up to 6 months after transplantation, and late PTA is defined as anemia which develops after 6 months. There are multiple causes, with iron deficiency being the major contributor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496140DOI Listing
April 2019
1 Read

Iron Deficiency Anemia in Chronic Kidney Disease.

Acta Haematol 2019 Apr 10;142(1):44-50. Epub 2019 Apr 10.

Nephrology and Hypertension Unit, Rabin Medical Center, Petah Tikva, Israel.

Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency. Absolute iron deficiency is defined by severely reduced or absent iron stores, while functional iron deficiency is defined by adequate iron stores but insufficient iron availability for incorporation into erythroid precursors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496492DOI Listing
April 2019
1 Read

Safety of Oral and Intravenous Iron.

Acta Haematol 2019 Apr 10;142(1):8-12. Epub 2019 Apr 10.

Division of Hematology/Medical Oncology, Department of Pathology and Pediatrics, Oregon Health and Science University, Portland, Oregon, USA,

As the adverse effects of iron deficiency are better recognized, the use of oral and intravenous iron has increased dramatically. Oral iron is often poorly tolerated, with up to 70% or more of patients noting gastrointestinal issues; this may affect adherence to therapy. In addition, many patients will not respond to oral iron due to their underlying illness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496966DOI Listing
April 2019
1 Read

Management of Iron Deficiency Anaemia in Inflammatory Bowel Disease.

Acta Haematol 2019 Apr 10;142(1):30-36. Epub 2019 Apr 10.

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria,

Inflammatory bowel disease (IBD) is a group of chronic relapsing inflammatory disorders affecting the large and small intestine, with a rising worldwide incidence and prevalence. Anaemia is the most common extraintestinal manifestation of IBD, correlating with disease activity, and tending to relapse even after successful therapy. Iron deficiency is the most common cause; however, it often manifests in combination with anaemia of inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496728DOI Listing
April 2019
1 Read

Management of Iron Deficiency in Heart Failure.

Acta Haematol 2019 Apr 10;142(1):51-56. Epub 2019 Apr 10.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel,

Anemia is a common finding in patients with heart failure (HF). The cause for anemia is multifactorial, with iron deficiency being the most common cause. Anemia with HF is an established predictor of morbidity and mortality. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/496822
Publisher Site
http://dx.doi.org/10.1159/000496822DOI Listing
April 2019
5 Reads

Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia.

Acta Haematol 2019 Apr 9;141(4):232-244. Epub 2019 Apr 9.

Hematology Biology, Nantes University Hospital, Nantes, France.

Diagnosis and classification of acute myeloid leukaemia (AML) require cytogenetic and molecular genetic investigation. However, while these evaluations are pending, morphology supplemented by immunophenotyping can provide clues to the diagnosis of specific cytogenetic/genetic categories of AML. Most importantly, acute promyelocytic leukaemia can be diagnosed with a high degree of certainty. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496097DOI Listing

Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?

Acta Haematol 2019 Apr 9;141(4):245-253. Epub 2019 Apr 9.

Department of Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Background: The incidence of venous thromboembolism (VTE) in haematological malignancies varies according to the type and grade of the disease and clinical variables, and there is a need to develop a tool to predict the occurrence of VTE in cancer patients at diagnosis to tailor prophylactic anticoagulation use during treatment.

Objective: To study the incidence of VTE in haematological malignancies and clarify whether vascular and inflammatory biomarkers could be used as predictors of VTE in those patients.

Methods: This was a prospective observational cohort study. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/496914
Publisher Site
http://dx.doi.org/10.1159/000496914DOI Listing
April 2019
4 Reads

Serum Vitamin D Levels in Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Analysis.

Acta Haematol 2019 Apr 9;141(4):225-231. Epub 2019 Apr 9.

Department of Medicine III, Hematology and Oncology, Technische Universität München, Munich, Germany.

Background/aims: There is growing evidence supporting the role of innate immune deregulation and inflammation in the pathogenesis of myelodysplastic syndromes (MDS). Vitamin D (VD) is known to be involved in various immune and epigenetic processes. This analysis aimed to evaluate serum VD levels in patients with MDS and to analyze associations between serum VD levels and disease characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496014DOI Listing
April 2019
1 Read

Introduction.

Acta Haematol 2019 Apr 9;142(1):5-7. Epub 2019 Apr 9.

Department of Medicine, Georgetown University School of Medicine, Washington, District of Columbia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496981DOI Listing

Five Ibrutinib-Associated Side Effects That All Clinicians Should Be Aware of.

Acta Haematol 2019 Apr 9;141(4):254-255. Epub 2019 Apr 9.

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel,

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497356
Publisher Site
http://dx.doi.org/10.1159/000497356DOI Listing
April 2019
1 Read

Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload.

Acta Haematol 2019 Apr 9;141(4):256-260. Epub 2019 Apr 9.

Department of Paediatrics, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada,

Hereditary spherocytosis (HS) is a common inherited haemolytic anaemia and has great variability in its presentation. Non-transfusion iron overload in HS has only been reported with co-inheritance of hereditary haemochromatosis (HHC). We present 4 unrelated patients of East Asian ethnicity with mild HS and significant non-transfusion iron overload in the absence of known disease-causing mutations in HHC genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497175DOI Listing
April 2019
1 Read
0.994 Impact Factor

Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.

Acta Haematol 2019 Apr 9;141(4):261-267. Epub 2019 Apr 9.

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

BCR-ABL1-negative myeloproliferative disorders and chronic myeloid leukaemia are haematologic malignancies characterised by single and mutually exclusive genetic alterations. Nevertheless, several patients co-expressing the JAK2V617F mutation and the BCR-ABL1 transcript have been described in the literature. We report the case of a 61-year-old male who presented with an essential thrombocythaemia phenotype and had a subsequent diagnosis of chronic phase chronic myeloid leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496821DOI Listing
April 2019
1 Read

Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia.

Acta Haematol 2019 Apr 4;141(4):222-224. Epub 2019 Apr 4.

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495779DOI Listing
April 2019
2 Reads

Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.

Acta Haematol 2019 Apr 3;141(4):216-221. Epub 2019 Apr 3.

Department of Hematology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel,

Background: The treatment of relapsed/refractory (R/R) peripheral T cell lymphoma (PTCL) is limited to a few agents. Romidepsin, a histone deacetylase inhibitor, was approved for PTCL treatment as a single agent in the R/R setting, yet with partial efficacy. Several attempts to combine romidepsin with other chemotherapy regimens have been reported, however, with significant toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000498905DOI Listing
April 2019
1 Read

The Muddied Waters of Ibrutinib Therapy.

Acta Haematol 2019 Apr 3;141(4):209-213. Epub 2019 Apr 3.

Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel.

A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors. This report includes a review of reported cases of Aspergillus infections in patients receiving ibrutinib and the shared features of these cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496555DOI Listing
April 2019
4 Reads

Promoter Mutation Analysis of LEPROTL1 Gene in Acute Leukemias and Solid Tumors.

Acta Haematol 2019 Apr 3;141(4):214-215. Epub 2019 Apr 3.

Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea,

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/494424
Publisher Site
http://dx.doi.org/10.1159/000494424DOI Listing
April 2019
3 Reads

Storage Iron Turnover from a New Perspective.

Authors:
Hiroshi Saito

Acta Haematol 2019 Apr 3;141(4):201-208. Epub 2019 Apr 3.

Department of Internal Medicine, Kawamura Hospital, Gifu, Japan,

Background/aims: Storage iron turnover has remained poorly understood since 1953. In addition, errors in measurements of the storage iron turnover rate (SIT) by ferrokinetics have been detected and the causes of those errors need to be elucidated.

Methods: A new, computer-assisted method, "serum ferritin kinetics," was introduced for the quantitation of ferritin iron and hemosiderin iron. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496324DOI Listing
April 2019
2 Reads

A Novel Association between Antiretroviral Therapy and Drug-Induced Immune Thrombocytopenia Purpura.

Acta Haematol 2019 6;141(3):199-200. Epub 2019 Mar 6.

Department of Haematology, St. Vincent's Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/496325
Publisher Site
http://dx.doi.org/10.1159/000496325DOI Listing
March 2019
3 Reads

Short-Term Fasting Induces Cell Cycle Arrest in Immature Hematopoietic Cells and Increases the Number of Naïve T Cells in the Bone Marrow of Mice.

Acta Haematol 2019 6;141(3):189-198. Epub 2019 Mar 6.

Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Calorie restriction (CR) has been studied as a way to prolong longevity, and CR before chemotherapy can reduce hematological toxicity in cancer patients. We investigated the influence of fasting on immune cells and immature hematopoietic cells. In fasted mice, there was a significant reduction in the hematopoietic stem cell count but no significant difference for progenitor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496096DOI Listing

Current Real-Life Results and Future Options of Gemcitabine-Based Salvage Therapy for Relapsed or Refractory Non-Hodgkin Lymphoma.

Acta Haematol 2019 5;141(3):187-188. Epub 2019 Mar 5.

Lymphoma Unit, Department of Hematology, Son Espases University Hospital, IdISBa, Palma de Mallorca, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496915DOI Listing
March 2019
1 Read

Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma.

Acta Haematol 2019 27;141(3):176-186. Epub 2019 Feb 27.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

Background: Peripheral T cell lymphoma (PTCL) is a heterogeneous entity with poor survival. We evaluated the neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and platelet count as new prognostic factors for PTCL.

Patients And Methods: We retrospectively analyzed 77 patients with PTCL initially treated with anthracycline-based chemotherapy. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/495337
Publisher Site
http://dx.doi.org/10.1159/000495337DOI Listing
February 2019
14 Reads

Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.

Acta Haematol 2019 26;141(3):164-175. Epub 2019 Feb 26.

Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China,

Background: The preferred type of postremission therapy (PRT) for intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate. Although allogeneic stem cell transplantation (alloSCT) is regarded as a curative strategy for AML, the efficacy of autologous stem cell transplantation (autoSCT) for patients without a matched sibling donor (MSD) has remained controversial.

Methods: To compare survival outcomes after alloSCT versus autoSCT for patients with intermediate-risk AML in CR1, we performed a meta-analysis of 11 clinical studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495206DOI Listing
February 2019

Time to Understand More about Spontaneous Regression of Cancer.

Authors:
Tamar Tadmor

Acta Haematol 2019 20;141(3):156-157. Epub 2019 Feb 20.

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496680DOI Listing
February 2019

TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report.

Acta Haematol 2019 20;141(3):158-163. Epub 2019 Feb 20.

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan,

TAFRO syndrome, a rare systemic inflammatory disease, can lead to multiorgan failure without appropriate treatment. Although thrombocytopenia is frequently seen in patients with TAFRO syndrome, little is known about its pathogenesis. Moreover, while recent studies have reported the presence of an anterior mediastinal mass in some patients, the pathological status of this remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492743DOI Listing
February 2019
1 Read
0.994 Impact Factor

Unmet Needs and Therapeutic Strategies in Cardio-Hemato-Oncology.

Acta Haematol 2018 24;140(4):226-230. Epub 2018 Oct 24.

Cardiology Department, Rabin Medical Center, Petach Tikva, Israel.

With the increasing survival of cancer patients and therapeutic advancements, the cardiovascular complications of therapy have become a significant issue. A dedicated, integrated team is important in providing the balance between acquiring a hematological/oncological response and cardiovascular morbidity and mortality. This article aims to shed light on this field - providing some examples of therapies with cardiotoxic potential as well as the cardiologist's approach to patient assessment before, during, and after therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493636DOI Listing
October 2018

Inhibitors: A Need for Eradication?

Acta Haematol 2019 15;141(3):151-155. Epub 2019 Feb 15.

Division of Hematology/Oncology, Department of Pediatrics and Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.

The development of inhibitors against factor VIII (FVIII) concentrates represents a significant treatment complication for hemophilia. Immune tolerance induction (ITI) therapy eradicates inhibitors in 60-80% of patients, resulting in a normal FVIII response. This article, based on presentations at the 6th International Coagulation Meeting, held in Barcelona, Spain, in September 2017, provides an overview of management approaches for patients with inhibitors and briefly tabulates four cases of ITI therapy (first-line or rescue ITI therapy in pediatric and adult patients) with successful outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495454DOI Listing
February 2019
1 Read

Case Report: Development of Factor VIII Inhibitor in a Patient with an Uncommon de novo Mutation in the Factor VIII Gene.

Acta Haematol 2019 15;141(3):129-134. Epub 2019 Feb 15.

Division of Pediatric Hematology/Oncology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA,

The development of factor VIII inhibitors remains a significant clinical challenge in the management of hemophilia A. We present a patient of mixed ethnicity with severe hemophilia A who was found to have a F8 gene hemizygous c.5815G>T mutation resulting in an Ala1939Ser substitution (Ala1920Ser in legacy nomenclature) and possible splice site change that has been reported in only 1 patient previously. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495559DOI Listing
February 2019
1 Read

Acquired Factor V Inhibitor with Symptoms and Titer of Inhibitor Differences: Report of Two Cases.

Acta Haematol 2019 15;141(3):148-150. Epub 2019 Feb 15.

Clinical Laboratory Center, The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496080DOI Listing
February 2019
1 Read

Replacement Therapy with Glu-Plasminogen for the Treatment of Severe Respiratory and Auditory Complications of Congenital Plasminogen Deficiency.

Acta Haematol 2019 15;141(3):146-147. Epub 2019 Feb 15.

Prometic Life Sciences, Laval, Québec, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495336DOI Listing
February 2019

Primary CNS Lymphoma in the Elderly: The Challenge.

Acta Haematol 2019 15;141(3):138-145. Epub 2019 Feb 15.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

Primary central nervous system (CNS) lymphoma is an aggressive brain tumor sensitive to chemotherapy and radiotherapy. Its incidence has increased in the elderly, and they account for the majority of patients. The median survival of patients older than 70 years did not change over the last 40 years and remained in the range of 6-7 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495284DOI Listing
February 2019

Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.

Acta Haematol 2019 6;141(2):119-127. Epub 2019 Feb 6.

Department of Pediatric Hematology-Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.

Background: The WHO defined myeloid and lymphoid neoplasms (MLN) with eosinophilia associated with PDGFRB, PDGFRA, FGFR1 rearrangements as a new entity in 2016. PDGFRB-rearranged MLN sensitive to imatinib were described in adult patients. We report the first pediatric patient with PDGFRB-rearranged myeloproliferative disorder associated with T-lymphoblastic lymphoma bearing the t(5; 14)(q33;q32) translocation who was successfully treated with imatinib only. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495687DOI Listing
February 2019
14 Reads

Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.

Acta Haematol 2019 6;141(2):111-118. Epub 2019 Feb 6.

Department of Medical Oncology, Ibaraki Prefectural Central Hospital, Kasama, Japan,

We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted of four 28-day cycles of once-weekly oral cyclophosphamide (300 mg/m2), subcutaneous bortezomib (1.3 mg/m2), and oral dexamethasone (40 mg). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495338DOI Listing
February 2019
3 Reads

Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.

Acta Haematol 2019 29;141(2):107-110. Epub 2019 Jan 29.

Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA,

Adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with conventional chemotherapy have dismal outcomes. Novel immunotherapies targeting CD19, including the bispecific T-cell engager blinatumomab and chimeric antigen-receptor T (CAR-T) cells, have revolutionized the treatment of R/R B-ALL. Robust response rates to CAR-T cell therapy after blinatumomab have recently been reported, but it is unknown whether blinatumomab can be effective following failure of anti-CD19 CAR-T cell therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495558DOI Listing
January 2019
1 Read

Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.

Acta Haematol 2019 16;141(2):93-106. Epub 2019 Jan 16.

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA,

The term amyloidosis refers to a group of disorders in which protein fibrils accumulate in certain organs, disrupt their tissue architecture, and impair the function of the effected organ. The clinical manifestations and prognosis vary widely depending on the specific type of the affected protein. Immunoglobulin light-chain (AL) amyloidosis is the most common form of systemic amyloidosis, characterized by deposition of a misfolded monoclonal light-chain that is secreted from a plasma cell clone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495455DOI Listing
January 2019
2 Reads

Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.

Acta Haematol 2019 10;141(2):84-90. Epub 2019 Jan 10.

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel,

Gemcitabine-based salvage therapy is considered an effective treatment for relapsed and refractory Non-Hodgkin's lymphoma (NHL). We analyzed the outcome of 41 consecutive NHL patients treated with gemcitabine-based regimens between January 2007 and October 2015. Twenty-eight males and 13 females (median age 66. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495283DOI Listing
January 2019
1 Read

Gemcitabine: End of a Chemotherapy's Era?

Authors:
Stephen D Smith

Acta Haematol 2019 10;141(2):91-92. Epub 2019 Jan 10.

Department of Internal Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496098DOI Listing
January 2019

Autoimmune Cytopenias Occurring after Treatment with Chemoimmunotherapy for Non-Hodgkin Lymphomas.

Acta Haematol 2019 10;141(2):79-83. Epub 2019 Jan 10.

Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.

Autoimmune diseases, including autoimmune hemolytic anemia and immune thrombocytopenic purpura, have been described in patients with non-Hodgkin lymphoma (NHL) after immunochemotherapy. However, the underlying pathogenesis remains unclear. We examined NHL patients with autoimmune cytopenia and all patients were treated with rituximab-containing therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495600DOI Listing
January 2019
3 Reads

Top 100 Most Influential Articles in the Field of Myeloid Neoplasms: A Bibliometric Study.

Acta Haematol 2019 7;141(2):68-78. Epub 2019 Jan 7.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Bibliometric analyses are a tool employed by researchers and funding agencies to establish the most important areas of research in a particular field, and to determine which foci need increased research attention. Such analyses have been published in a variety of clinical specialties; however, a detailed literature search showed that no such study has been done for "myeloid neoplasms." In order to bridge this gap, we conducted a citation analysis of the 100 most influential articles on myeloid neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493251DOI Listing
January 2019
8 Reads

Is BK Virus-Associated Cystitis a Generalized Epithelial Disease?

Acta Haematol 2019 3;141(2):65-67. Epub 2019 Jan 3.

Department of Haematology/Oncology, University Medicine Greifswald, Greifswald, Germany.

BK polyomavirus-associated haemorrhagic cystitis (BKHC) is a complication after allogeneic stem cell transplantation, which can occur in 5-60% of the cases. BK viruria alone can also occur in up to 100%. BKHC can lead to severe morbidity in stem cell-transplanted patients, but data about this disease is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494748DOI Listing
January 2019

Ankyrin Mutations in Hereditary Spherocytosis.

Acta Haematol 2019 2;141(2):63-64. Epub 2019 Jan 2.

University of Utah Health, Department of Pathology/ARUP Laboratories, Salt Lake City, Utah, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495339DOI Listing
January 2019
1 Read

Hemophagocytic Lymphohistiocytosis during the Postpartum Stage of Pregnancy: A Report of Eight Cases.

Acta Haematol 2019 7;141(1):55-60. Epub 2018 Dec 7.

Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China,

Haemophagocytic lymphohistiocytosis (HLH) is a rare and severe clinical syndrome that can be classified as either primary or secondary. Secondary HLH can be triggered by a variety of diseases. Pregnancy-related HLH has already been observed clinically. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493879DOI Listing
December 2018
3 Reads

Postpartum Hemophagocytic Lymphohystiocytosis: A New Entity Is Born.

Acta Haematol 2019 7;141(1):61-62. Epub 2018 Dec 7.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495340DOI Listing
December 2018
2 Reads

Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.

Acta Haematol 2019 30;141(1):32-42. Epub 2018 Nov 30.

Department of Pediatrics, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.

Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies. In this study, a systematic meta-analysis was performed to assess the effectiveness and safety of DFX in the treatment of thalassemia with iron overload. We performed a systematic electronic literature search for randomized controlled studies of DFX in the Embase, Medline, Cochrane, and Chinese Biomedical Literature (CBM) databases from January 1990 to May 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494487DOI Listing
November 2018
2 Reads

Factors Involved in the Selection of Treatment in Patients with Hematological Malignancies.

Acta Haematol 2019 5;141(1):54. Epub 2018 Dec 5.

Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493569DOI Listing
December 2018
2 Reads

Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.

Acta Haematol 2019 5;141(1):43-53. Epub 2018 Dec 5.

Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China,

Background/aims: The aim of this work was to investigate the efficacy and predictive factors of CLAG treatment in refractory or relapsed (R/R) acute myeloid leukemia (AML) patients.

Methods: Sixty-seven R/R AML patients were enrolled in this prospective cohort study and treated by a CLAG regimen: 5 mg/m2/day cladribine (days 1-5), 2 g/m2/day cytarabine (days 1-5), and 300 μg/day filgrastim (days 0-5). The median follow-up duration was 10 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493250DOI Listing
December 2018
2 Reads
0.994 Impact Factor